Canakinumab treatment reduced CRP and IL-6 concentrations, however, there was no effect on HbA1c or risk of new-onset type 2 diabetes, supporting that low-grade inflammation is not causal for type 2 diabetes and that this treatment will not have effect on type 2 diabetes. Here, CRP is linked to type 2 diabetes mellitus.